PAM
JUNO

Princeton Alpha Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Princeton Alpha Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-22,473
Closed -$674K – 975
2016
Q3 		$674K Buy
+22,473
New +$699K 0.13% 262

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Princeton Alpha Management's JUNO Position: Q4 2016 in Review

Princeton Alpha Management sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2016, closing a stake of 22,473 shares — an estimated $674K sold.

Princeton Alpha Management first reported a position in JUNO in Q3 2016 and held it in 1 quarter. The position peaked at $674K in Q3 2016. 159 funds tracked by Wall St. Rank hold JUNO as of Q4 2016.

  • Princeton Alpha Management reported no remaining Juno Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Princeton Alpha Management sold 22,473 Juno Therapeutics, Inc. shares in Q4 2016, an estimated $674K.
  • Princeton Alpha Management first reported a position in Juno Therapeutics, Inc. in Q3 2016 and held it in 1 quarter.
  • Princeton Alpha Management's Juno Therapeutics, Inc. position peaked at $674K in Q3 2016.
  • 159 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2016.

Based on Princeton Alpha Management's 13F filing for Q4 2016, filed 10 Feb 2017.